Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Commentary|Videos|April 17, 2026
Oncology PulsePoints: ASCO WBC Growth Factors Guidelines Update
Fact checked by: Nicole Canfora Lupo
Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.
Advertisement
Advertisement
The use of white blood cell (WBC) growth factors in oncology has continued to evolve alongside expanding evidence supporting individualized approaches to neutropenia prevention and management. The latest guideline update from the American Society of Clinical Oncology (ASCO) reflects nearly a decade of new data since its last revision in 2015, incorporating updated evidence grading, expanded guidance on shared decision-making, and greater flexibility in dosing and administration strategies.
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Advertisement
Advertisement